Editorial

Towards an integral clinical proton dose prediction uncertainty by considering delineation variation

Proton therapy is more susceptible to uncertainties of the beam placement compared to conventional radiotherapy due to the finite range of protons in the patient. To ensure target coverage, additional healthy tissue around the target volume is irradiated in clinical routine. Advancements in both patient imaging and treatment planning therefore aim to reduce these clinical safety margins. However, any reduction of the overall safety margin also reduces the possibility to compensate for uncertainty sources that are not explicitly considered in the uncertainty estimation and therefore comes with a risk of decreased target coverage [1]. At the same time, an appropriate technique for combining and considering the different uncertainties in the treatment planning process is necessary as not to dilute technical advancements.

Uncertainties in proton therapy planning and delivery originate from the whole treatment chain, starting from patient imaging and the subsequent target and organ-at-risk delineation, across to treatment planning, patient positioning and finally beam delivery, with each uncertainty factor in itself describing a combination of different uncertainties [2]. Several approaches to combine errors in radiotherapy have been investigated, such as the straightforward calculation of (weighted) sums where assumptions regarding the error distribution are implicitly included [2,3], or more complex approaches such as numerical error sampling, relying on probability density functions (PDFs) [4,5]. A comprehensive framework for combining Type A uncertainties (those obtained as standard deviation from repeated measurements) and Type B uncertainties (those based on scientific judgement by assigning PDFs) is given in the Guide to the expression of Uncertainty in Measurement [6], which has also been applied for uncertainty estimation in proton therapy [7,8]. Resulting uncertainty factors regarding patient setup, range prediction and organ motion can furthermore be considered in treatment planning by examining dose distributions for different error scenarios [9–12].

A major uncertainty factor, considered only implicitly as part of the safety margin, is the target delineation. It depends not only on the available image information, which is ambiguous due to microscopical anatomical spread not being visible – typically considered by increasing the gross tumor volume by several millimeters, depending on the tumor site – but also on the level of training received by the clinician performing the delineation (the ‘observer’), leading to large inter-observer variation (IOV) depending on the skill level. With the risk of treatment-center-specific systematic deviations, e.g. due to different interpretation of clinical guidelines, this potentially makes delineation the weakest link in accurate proton treatment planning. This can only be intercepted by (large) safety margins [13].

However, no consensus on the necessary level of uncertainty exists yet. While numerous studies were performed, they lack methodological consistency, making it difficult to pin down an uncertainty to cover both the accuracy and variation in delineation [14]. There is only limited data on the resulting variation in target expansion between treatment centers. While for prostate cancer- and brain tumor patients the variation is on the level of or exceeding patient setup-ups errors [15], the target expansion varies greatly in the heterogeneous head and neck region, ranging from 0 to 15 mm between treatment centers [16].

The presented work by Hofmaier et al. [17], published in this virtual special issue of physics highlight papers from the recent ESTRO 2021 conference, quantitatively assesses the impact on calculated dose of IOV in target delineation in combination with uncertainties in patient setup and range prediction. The work utilizes a Monte-Carlo variance-based sensitivity analysis framework [18] for error combination, where input parameters are sampled from assumed uncertainty distributions as well as from a set of delineations to quantify their influence on dose calculation and consequently dose/volume parameters. The approach allows for a direct, patient-specific quantification of the individual uncertainty factors, which can be used to support decision making in the clinical plan evaluation process. For individual patients in a small cohort of benign skull base meningioma patients, the authors traced back relevant deteriorations on D95% of the clinical target volume to the variations in delineation.

It should be noted that their specific metric for the IOV was calculated from different target volume delineations and a consensus target volume obtained with the STAPLE algorithm [19]. This makes the presented results susceptible to individual delineations deviating from the group, as also pointed out by the authors. A different metric choice may lead to completely different results. The presented work is therefore first of all a feasibility study on how delineation uncertainties in proton therapy can be considered on a patient-individual level as part of a sensitivity analysis. At the same time, a major benefit of the framework is its adaptability in including different uncertainty sources, such as relative biological effectiveness, as done in previous publications from the authors [20], with the major limiting factor being computation time. A future application of the presented framework on a larger patient cohort of primary brain tumor- as well as pelvic cancer patients may allow for a better understanding of the degree to which current clinical safety margins cover variations in delineation. There, an IOV metric more robust against outliers is needed. In clinical routine, where the labor-intensive delineation by multiple clinicians is generally unfeasible, the application of the framework on contours from different automated delineation approaches may prove beneficial to identify patients either requiring larger or allowing for smaller safety margins.
Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: OncoRay has an institutional research agreement with Siemens Healthineers in the field of dual-energy CT for particle therapy (2016–2020). Furthermore, OncoRay has an institutional agreement as reference center for dual-energy CT in radiotherapy as well as a software evaluation contract with Siemens Healthineers.

References

[1] Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer 2016;16:234–49. https://doi.org/10.1038/nrc.2016.18.

[2] Pagani H. Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys Med Biol 2012;57:R99–117. https://doi.org/10.1088/0031-9155/51/11/R99.

[3] Yang M, Zhu XR, Park PC, Titt U, Mohan R, Virshup G, et al. Comprehensive analysis of proton range uncertainties related to patient stopping-power-ratio estimation using the stoichiometric calibration. Phys Med Biol 2012;57:4095–115. https://doi.org/10.1088/0031-9155/51/13/4095.

[4] Bar E, Lalonde A, Royle G, Lu H-M, Bouchard J. The potential of dual-energy CT to reduce proton beam range uncertainties. Med Phys 2017;44:2332–44. https://doi.org/10.1002/mp.12215.

[5] Rizzoglio V, Adelmann A, Gerbershagen A, Meer D, Nesteruk KP, Schippers JM. Uncertainty quantification analysis and optimization for proton therapy beam lines. Phys Medica 2020;75:11–8. https://doi.org/10.1016/j.ejmp.2020.05.013.

[6] ISO. Guide to the Expression of Uncertainty in Measurement. Geneva, Switzerland: International Organization for Standardization; 2008.

[7] Berthold J, Khamfongkhruea C, Petzold J, Thiele J, Holscher T, Wohlfahrt P, et al. First-in-human validation of CT-based proton range prediction using prompt gamma imaging in prostate cancer treatments. Int J Radiat Oncol Biol Phys 2021;111:1033–43. https://doi.org/10.1016/j.ijrobp.2021.06.036.

[8] Peters N, Wohlfahrt P, Hofmann C, Möhler C, Menkel S, Tschiche M, et al. Reduction of clinical safety margins in proton therapy enabled by the clinical implementation of dual-energy CT for direct stopping-power prediction. Radiother Oncol 2022. https://doi.org/10.1016/j.radonc.2021.11.002.

[9] Fredriksson A, Forsgren A, Hikidemark B. Minimax optimization for handling range and setup uncertainties in proton therapy. Med Phys 2011;38:1672–84. https://doi.org/10.1118/1.3556559.

[10] Pföffelder D, Wilkens JJ, Oelfke U. Worst case optimization: A method to account for uncertainties in the optimization of intensity modulated proton therapy. Phys Med Biol 2008;53:1689–700. https://doi.org/10.1088/0031-9155/53/6/013.

[11] Liu W, Zhang X, Li Y, Mohan R. Robust optimization of intensity modulated proton therapy. Med Phys 2012;39:1079–91. https://doi.org/10.1118/1.3679345.

[12] Unkelbach J, Pagani H. Robust proton treatment planning: Physical and biological optimization. Semin Radiat Oncol 2018;28:88–96. https://doi.org/10.1016/j.sradonc.2017.11.005.

[13] Njeh CF. Tumor delineation: The weakest link in the search for accuracy in radiotherapy. J Med Phys 2006;33:136–40. https://doi.org/10.1010/0971-6203.44472.

[14] Vinod SK, Jameson MG, Min M, Holloway LC. Uncertainties in volume delineation in radiation oncology: A systematic review and recommendations for future studies. Radiother Oncol 2016;121:169–79. https://doi.org/10.1016/j.radonc.2016.09.009.

[15] Segedin B, Petric P. Uncertainties in target volume delineation in radiotherapy - Are they relevant and what can we do about them? Radiol Oncol 2016;50:254–62. https://doi.org/10.1515/raon-2016-0023.

[16] Hong TS, Tomé WA, Harari PM. Heterogeneity in head and neck IMRT target design and clinical practice. Radiother Oncol 2012;103:92–8. https://doi.org/10.1016/j.radonc.2012.02.010.

[17] Hofmaier J, Walter F, Hadi I, Rottler M, von Bestenhostel R, Dedes G, et al. Combining inter-observer variability, range and setup uncertainty in a variance-based sensitivity analysis for proton therapy. Phys Imaging Radiat Oncol 2021;20:117–20. https://doi.org/10.1016/j.phro.2021.11.005.

[18] Saltelli A, Annoni P, Azinzio I, Campolongo F, Ratto M, Tarantola S. Variance based sensitivity analysis of model output. Design and estimator for the total sensitivity index. Comput Phys Commun 2010;181:259–70. https://doi.org/10.1016/j.cpc.2009.09.018.

[19] Warfield SK, Zou KH, Wells WM. Simultaneous Truth and Performance Level Estimation (STAPLE): an algorithm for the validation of image segmentation. IEEE Trans Med Imaging 2004;23:903–21. https://doi.org/10.1109/TMI.2004.828354.

[20] Hofmaier J, Dedes G, Carlson DJ, Parodi K, Belka G, Kamp F. Variance-based sensitivity analysis for uncertainties in proton therapy: A framework to assess the effect of simultaneous uncertainties in range, positioning, and RBE model predictions on RBE-weighted dose distributions. Med Phys 2021;48:805–18. https://doi.org/10.1002/mp.10596.

Nils Peters,a,b Ludvig P. Muren,c,d a Oncoray – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany b Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany c Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark d Department of Clinical Medicine, Aarhus University, Aarhus, Denmark